Orion PharmaDHA:ORIONPHARM 71 Return-on-Tangible-Equity is -3.03% as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.26 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 425 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 73.88% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orion Pharma's annualized net income for the quarter that ended in Mar. 2026 was BDT-607 Mil. Orion Pharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was BDT20,031 Mil. Therefore, Orion Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -3.03%.
The historical rank and industry rank for Orion Pharma's Return-on-Tangible-Equity or its related term are showing as below:
DHA:ORIONPHARM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3.56 Med: 4.61 Max: 6.4
Current: -3.56
During the past 12 years, Orion Pharma's highest Return-on-Tangible-Equity was 6.40%. The lowest was -3.56%. And the median was 4.61%.
DHA:ORIONPHARM's Return-on-Tangible-Equity is ranked worse than 73.88% of 425
companies
in the Utilities - Independent Power Producers industry
Industry Median: 4.71
vs DHA:ORIONPHARM: -3.56
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Orion Pharma Return-on-Tangible-Equity Related Terms
Orion Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Return-on-Tangible-Equity Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Return-on-Tangible-Equity vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -3.03% mean?
Orion Pharma (DHA:ORIONPHARM) has a Return-on-Tangible-Equity of -3.03% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #314 out of 425 companies in the Utilities - Independent Power Producers industry, placing it in the top 73.9%.
Is Orion Pharma's Return-on-Tangible-Equity too high?
Orion Pharma's current Return-on-Tangible-Equity is -3.03%. Based on the distribution chart, Orion Pharma ranks #314 out of 425 companies in the Utilities - Independent Power Producers industry, which is below the industry midpoint. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Return-on-Tangible-Equity compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #314 out of 425 companies for Return-on-Tangible-Equity. This places Orion Pharma in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Utilities - Independent Power Producers company?
The median Return-on-Tangible-Equity among Utilities - Independent Power Producers companies is 4.71, based on 425 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Return-on-Tangible-Equity is 4.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Return-on-Tangible-Equity is -3.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.26, compared to a current price of BDT28.30 — trading 39.7% above its estimated fair value. The current Return-on-Tangible-Equity is -3.03%. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Return-on-Tangible-Equity is -3.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.30 is trading 39.7% above its estimated GF Value™ of BDT20.26.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Return-on-Tangible-Equity: -3.03%
GF Value™: BDT20.26 vs. price of BDT28.30 (39.7% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
